• About
  • Vision
  • Origins
  • Team
  • Science
  • Rewriting RNA
  • Ascidian's Approach
  • Publications & Presentations
  • Pipeline
  • Programs
  • News
  • Press Releases
  • In the News
  • Careers
  • Ascidian Life
  • Opportunities

Get in Touch

LinkedIn Twitter

News
In the News

  • Press Releases
  • In the News

August 16, 2023 | PharmaVoice

Biotech Roundtable: Driving Success in Rare Diseases

April 27, 2023 | Ophthalmology Times

ARVO LIVE: Ascidian Therapeutics’ research into gene therapy

March 16, 2023 | Cell & Gene Podcast

The Potential Of RNA Exon Editing With Ascidian Therapeutics’ Romesh Subramanian, Ph.D.

March 6, 2023 | Nature Biotechnology

Shoot the messenger: RNA editing is here

February 14, 2023 | Drug Discovery News

Gene editing: DNA versus RNA

December 15, 2022 | PM360

PM360 2022 Innovative Startup: Ascidian Therapeutics

October 13, 2022 | The Boston Globe

Boston startup Ascidian Therapeutics charts vision for therapies that “rewrite RNA”

October 12, 2022 | MedCity News

Sea creature-inspired biotech Ascidian surfaces with $50M and a new way to edit RNA

October 12, 2022 | labiotech.eu

Ascidian Therapeutics launches with $50M to rewrite RNA

October 12, 2022 | GENETIC ENGINEERING & BIOTECHNOLOGY NEWS

Ascidian Therapeutics Launches With RNA Exon Editing Platform

12Next

COPYRIGHT © ASCIDIAN THERAPEUTICS, INC. | ALL RIGHTS RESERVED.

Terms of Use Privacy Policy
LinkedIn Twitter

outreach@ascidian-tx.com ASCIDIAN THERAPEUTICS
80 GUEST STREET
FOURTH FLOOR
BOSTON MA 02135

ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE SCIENCES COMPANIES.

Back to top